Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ovation Pharmaceuticals, Inc.

Barry Deutsch1

  • 1Ovation Pharmaceuticals, Inc., 1 Overlook Point, Lincolnshire, IL 60069, USA. bdeutsch@ovationpharma.com

Pharmacogenomics
|November 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles

Ovation Pharmaceuticals addresses unmet medical needs by acquiring and revitalizing underpromoted drugs in CNS and oncology. This strategy was bolstered by a significant $150 million private equity investment, enabling product acquisitions.

Area of Science:

  • Pharmaceutical industry
  • Specialty pharmaceuticals
  • Drug development

Background:

  • Ovation Pharmaceuticals operates as a privately held specialty pharmaceutical company.
  • The company targets therapeutic areas with specialized physician networks, including central nervous system (CNS) disorders and oncology.
  • Ovation focuses on unmet medical needs within these niche markets.

Purpose of the Study:

  • To acquire and actively promote underpromoted branded pharmaceutical products.
  • To develop promising late-stage products that larger companies are no longer actively pursuing.
  • To enhance acquired products through sales, marketing, and clinical development.

Main Methods:

  • Acquisition of underpromoted or neglected pharmaceutical products.

Related Experiment Videos

  • Implementation of active sales and marketing strategies.
  • Investment in clinical development for new formulations and indications.

    • Main Results:

    • Secured $150 million in private equity financing in April 2002, a substantial investment for an early-stage specialty firm.
    • Acquired the first two products in August 2002 using a portion of the new funding.
    • Established a business model focused on revitalizing existing pharmaceutical assets.

    Conclusions:

    • Ovation Pharmaceuticals employs a strategic model to address unmet medical needs in specialized therapeutic areas.
    • Significant financial backing enables the acquisition and enhancement of pharmaceutical products.
    • The company's approach offers a pathway for underpromoted drugs to reach patients and improve therapeutic outcomes.